Curated News
By: NewsRamp Editorial Staff
February 20, 2026
MangoRx's $99 TRT Program Sees 336% Sales Surge, Disrupting Men's Health
TLDR
- Mangoceuticals' $99 monthly TRT program offers a cost-effective advantage in the growing $2.2 billion hormone therapy market with 336% sales growth and 54% lower acquisition costs.
- Mangoceuticals' all-inclusive TRT program operates through telehealth consultations, medical provider reviews, and pharmacy fulfillment for $99 monthly covering visits, labs, and medication.
- Mangoceuticals' affordable telehealth TRT program improves men's health accessibility through convenient hormone solutions that enhance wellness and quality of life.
- Mangoceuticals' TRT program saw 336% sales growth in its first month while reducing customer acquisition costs by 54% through its telehealth platform.
Impact - Why it Matters
This news matters because it signals a significant shift in how men access and afford critical healthcare. Testosterone replacement therapy is often essential for managing conditions like hypogonadism, which can impact energy, mood, and overall quality of life, but traditional pathways can be costly and inconvenient. MangoRx's model—offering comprehensive care for a flat, low monthly fee via telehealth—directly addresses barriers of cost, stigma, and access. The dramatic sales increase and reduced acquisition costs suggest the model resonates strongly with consumers. If this trend continues, it could pressure traditional healthcare providers and pharmacies to adopt more transparent, patient-centric pricing and delivery models, potentially making hormone health and other specialized treatments more accessible and affordable for a broader population. Furthermore, its success could accelerate investment and innovation in the digital health and telemedicine space, particularly for men's wellness.
Summary
Mangoceuticals (NASDAQ: MGRX), operating under the MangoRx and PeachesRx brands, has announced remarkable initial success for its newly launched all-inclusive injectable testosterone replacement therapy (TRT) program. The program, priced at an accessible $99 per month, bundles doctor visits, consultations, lab work, and prescribed medication into a single, convenient telehealth offering. Since its mid-December launch, the company reports a staggering 336% month-over-month sales increase for the injectable TRT program, coupled with a 54% decline in customer acquisition costs. This surge reflects a growing consumer demand for streamlined, affordable hormone health solutions delivered through digital platforms like MangoRx's secure telemedicine service. The company positions TRT as a primary growth driver, alongside its oral formulations such as PRIME by MangoRx powered by Kyzatrex, as it aims to capture a share of the global TRT market, which is estimated to reach approximately $2.1 to $2.2 billion by 2025.
MangoRx is a men's health and wellness company focused on developing and delivering pharmaceutical-based products via its telemedicine platform. Its current portfolio extends beyond TRT to include treatments for erectile dysfunction, hair growth, and weight management. The process for consumers is designed to be seamless: prescription requests are reviewed by licensed medical providers and, if approved, medications are fulfilled and discreetly shipped directly to the patient's doorstep through a partner compounding pharmacy. This model emphasizes convenience, privacy, and accessibility in men's healthcare. The news was disseminated through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on the biotechnology and life sciences sectors, providing enhanced press release distribution and corporate communications solutions to reach investors and the public effectively.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, MangoRx's $99 TRT Program Sees 336% Sales Surge, Disrupting Men's Health
